Navigation Links
MedSolutions Launches Implantable Cardiac Defibrillator Program to Reduce Unnecessary Surgeries
Date:11/18/2011

FRANKLIN, Tenn., Nov. 18, 2011 /PRNewswire/ -- MedSolutions, a leading provider of quality-driven medical cost management services, today announced the launch of its Implantable Cardioverter Defibrillator (ICD) Surgery Management Program, which uses evidence-based guidelines to ensure the clinical appropriateness of ICD and CRT-D (cardiac resynchronization therapy defibrillator) implantation.

With the cost of each ICD/CRT-D procedure averaging $34,000* and 157,082 procedures being performed annually, the ICD/CRT-D market represents approximately $5.3 billion in cost per year in the United States.(1) In addition, the estimated annual growth rate of ICD/CRT-D procedures is 11% to 14% respectively.(2)

While clinical guidelines dictate waiting three months after diagnosis of heart failure and at least 40 days after a heart attack before ICD/CRT-D implantation, many physicians take a more aggressive approach to surgery. Earlier implantation has not been shown to benefit patients and, in some cases, the physicians or facilities providing the surgery may lack knowledge of evidence-based guidelines for ICD implants.(3)  

Studies have shown that as many as 22.5% of ICD/CRT-D surgeries fail to meet established clinical guidelines, putting patients at greater risk for serious complications, including cardiac perforation, infection, and even death. According to one recent study, patients who received an ICD despite failing to meet evidence-based guidelines had "significantly higher" risks of post-procedure complications and in-hospital death, as well as longer hospital stays, than individuals who met evidence-based criteria.(4)

"ICD surgery is an effective and beneficial treatment for tens of thousands of patients, but it can be extremely harmful when performed outside of accepted guidelines," said Gregg Allen, M.D., chief medical officer of MedSolutions. "Not only do unnecessary ICD surgeries put patients at risk for a number of life-threatening issues, they also represent avoidable health care costs of up to $36,000 per procedure,(5) not including co-pays or additional costs to treat adverse outcomes."

MedSolutions' Implantable Cardioverter Defibrillator Surgery Management program uses evidence-based clinical guidelines built upon the latest guidelines from the American College of Cardiology, American Heart Association, and Heart Rhythm Society and provides a dedicated cardiac queue, including cardiologists and nurses experienced with the complexities of cardiac care, to determine whether ICD implantations are clinically appropriate.

"By reducing unnecessary and inappropriate ICD/CRT-D surgeries, our program helps improve health outcomes while limiting unnecessary costs associated with the procedure," Dr. Allen said. "As a result, members experience improved outcomes and payors can reduce total claims costs related to cardiac implantables by 10% to 15%."

About MedSolutionsUsing independently validated savings methodologies, MedSolutions specializes in quality-driven intelligent cost management of medical services for commercial, Medicare, and Medicaid payors. The company maintains management contracts for more than 33 million individuals nationwide. Using robust data, predictive intelligence technology and evidence-based clinical expertise, the company's innovative solutions extend beyond Radiology Management to other areas of medical specialty, including Oncology, Cardiac Imaging, Sleep, Ultrasound, Lumbar Spine Surgery, and MedSolutions' groundbreaking Premerus® Diagnostic Accuracy program – the nation's first solution for reducing diagnostic error rates to improve the quality and cost of care. MedSolutions has been recognized for outstanding customer service and effective call center management by the International Customer Management Institute and for four consecutive years by the prestigious J.D. Power and Associates Award. Visit www.medsolutions.com. Contact:

Rebecca KirkhamLovell Communications(615) 297-7766(1) Combination of the following 3 references: Hammill, et al. (July 16, 2010). "Review of the Registry's Fourth Year, incorporating Lead Data and Pediatric ICD Procedures, and Use as a National Performance Measure." National ICD Registry Annual Report 2009; Boston Strategic Partners, Inc. (September 2011). "Cardiac Procedure Cost Assessment;" and Boston Scientific. (July 30, 2010). "CMS Issues 2011 Final Inpatient Rule: CRM Reimbursement Update." *34,000 is the average Medicare/Medicaid cost with $5,000 for professional fees.

(2) Sg2. (2011). "Impact of Change" v. 10.0, NIS Analysis

(3) Al-Khatib, et al. (January 5, 2011).  "Non-Evidence-Based ICD Implantations in the United States." JAMA 305.1:43-49,26 http://jama.ama-assn.org/content/305/1/43.full

(4) Ibid, 3

(5) Boston Strategic Partners. (September 2011) "Cardiac Procedure Cost Assessment."  


'/>"/>
SOURCE MedSolutions
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. MedSolutions Suggests Use of Technology to Expand Access to Expertise Is Key to Early Breast Cancer Diagnosis and Treatment
2. MedSolutions Applauds Renewed Focus on the Dangers of Radiation Exposure
3. MedSolutions Offers Free CME Credit Imaging Safety Webinar for Physicians
4. MedSolutions Introduces Spine Surgery Management Program
5. MedSolutions Announces Program to Reduce Unnecessary Implantable Cardiac Defibrillator Surgeries
6. Iomai Launches Phase 1/2 Safety Study of Dose-Sparing Patch for Use With Pandemic Influenza Vaccine
7. Keeping the Data Center Clean: ATEN Launches Industry-First KVM Switches with Antimicrobial Nanocoating to Protect Products from Bacteria Surviving on Surfaces
8. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
9. Tengion Launches Second Phase 2 Clinical Trial of Regenerated Human Organ
10. Strategic Diagnostics Launches Initial Oncology-Targeted Antibody Reagent Catalog
11. deCODE Launches Phase II Clinical Testing of DG051 for the Prevention of Heart Attack
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2016)... Feb. 9, 2016  Jazz Pharmaceuticals plc (Nasdaq: ... 2015 fourth quarter and full year financial results on ... financial markets.  Company management will host a live audio ... p.m. GMT to discuss fourth quarter and full year ... update and guidance for 2016 financial results. ...
(Date:2/9/2016)... -- Amarantus BioScience Holdings, Inc. (OTCQB: ... Regenerative Medicine, Neurology and Orphan Diseases, today announced that ... Capital Group,s 2016 Disruptive Growth & Healthcare Conference which ... New York City . The Company,s presentation will ... pm by Gerald E. Commissiong , President & ...
(Date:2/9/2016)... "Global Blood Monitoring & Cardiac Monitoring Devices Market Assessment & Forecast: ... global market for blood monitoring & cardiac monitoring devices was valued ... US$ 24,830.1 million by 2019 at a CAGR of 6.8% from ... Europe , Asia-Pacific , ... Africa . The three major factors determining growth of ...
Breaking Medicine Technology:
(Date:2/9/2016)... ... February 09, 2016 , ... February is Heart Awareness ... Rate Variability scans throughout the month to the American Heart Association, New Mexico chapter. ... signs of heart disease and Health Quest’s INSiGHT Pulse Wave Profiler utilizes a non-invasive ...
(Date:2/9/2016)... ... February 09, 2016 , ... A new study ... rates and Medicare rates for a variety of medical services in Illinois as ... of the 2015 Fee Schedule Rates in Illinois, are professional medical services, ...
(Date:2/9/2016)... California (PRWEB) , ... February ... ... automated print and e-book publishing software, in partnership with Snowfall4pod Digital, creators ... – a comprehensive book publishing, content management, global distribution and print-on-demand network. ...
(Date:2/9/2016)... ... February 09, 2016 , ... Establishment Labs, a global breast implant ... to the company´s Board of Directors. , “We are honored to welcome ... exceptional entrepreneur.” said Juan Jose Chacon Quiros, CEO of Establishment Labs. "David’s knowledge and ...
(Date:2/9/2016)... ... ... Journal of Pain Research has published the commentary “ Terminology of chronic ... John F. Peppin says “Terminology matters, yet little attention has been paid to the ... pain’ and ‘chronic non-cancer pain’ are replete in the literature; however, the distinction here ...
Breaking Medicine News(10 mins):